Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: A UK evaluation using discrete-event simulation

PharmacoEconomics

Volumn 28, Issue 5, 2010, Pages 411-427

  Getsios, Denis ^a   Blume, Steve ^a   Ishak, K Jack ^b   Maclaine, Grant D H ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNITED BIOSOURCE CORPORATION   (Canada)

^c EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR CHANGE; CAREGIVER; CLINICAL TRIAL; COGNITION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; SIMULATION; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; CAREGIVERS; COMPUTER SIMULATION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DRUG COSTS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; INDANS; MALE; MODELS, ECONOMIC; NOOTROPIC AGENTS; PIPERIDINES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; TREATMENT OUTCOME;

EID: 77951443851     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11531870-000000000-00000     Document Type: Article

References (36)

1. Knapp M, Prince M, Albanese E, et al., for Kings' College London and London School of Economics. Dementia UK 2007. London: Alzheimer's Society, 2007 [online]. Available fromURL: http://www.alzheimers.org.uk/site/scripts/down load-info.php?fileID=2 [Accessed 2008 Dec 9]
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD005593
3. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3 (2): 211-225
4. Cohen JT, Neumann PJ. Decision analytic models for Alzheimer's disease: state of the art and future directions. Alzheimers Dement 2008; 4: 212-222
5. Green C. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for costeffectiveness analysis. Pharmacoeconomics 2007; 25 (9): 735-750
6. Oremus M. Systematic review of economic evaluations of Alzheimer's disease medications. Expert Rev Pharmacoecon Outcomes Res 2008; 8 (3): 273-289
7. National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London: NICE, 2006 Nov [online]. Available from URL: http://guidance.nice.org.uk/TA111 [Accessed 2008 Dec 9]
8. Caro JJ, Getsios D,Migliaccio-Walle K, et al., for the ASG. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 2001; 57: 964-971
9. GetsiosD,Migliaccio-WalleK, Caro JJ.NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? Pharmacoeconomics 2007; 25 (12): 997-1006
10. Pelosi AJ, McNulty SJ, Jackson GA. Role of cholinesterase inhibitors in dementia care needs rethinking. BMJ 2006; 333: 491-493
11. Dyer C. Appeal Court rules that NICE procedure was unfair. BMJ 2008 May 10; 336 (7652): 1035
12. Bosanquet N, Yeates A. Modelling the cost-effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 2006; 24 (6): 623-625
13. Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease. CNS Drugs 2007; 21 (3): 177-184
14. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebocontrolled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57 (3): 481-488
15. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57 (3): 489-495
16. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57 (4): 613-620
17. CERAD: Consortium to Establish a Registry for Alzheimer's Disease [online]. Available from URL: http://cerad. mc.duke.edu/Default.htm [Accessed 2009 Mar 6]
18. Rogers SL, FarlowMR, Doody RS, et al. A 24-week, doubleblind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50 (1): 136-145
19. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158 (9): 1021-1031
20. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69 (5): 459-469
21. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallelgroup, placebo-controlled study. Lancet 2006; 367 (9516): 1057-1065
22. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58 (3): 427-433
23. Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21 (5-6): 353-363
24. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151: 390-396
25. Mendiondo MS, Ashford JW, Kryscio RJ, et al. Modelling Mini Mental State Examination changes in Alzheimer's disease. Stat Med 2000; 19: 1607-1616
26. Mohs RC, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med 2000; 19: 1401-1409
27. Doody R, Geldmacher D, Gordon B, et al., for the Donepezil Study G. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol 2001; 58: 427-433
28. Lyle S, Grizzell M, Willmott S, et al. Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned.DementGeriatr Cogn Disord 2008; 25: 226-231
29. Xie J, Brayne C, and the Medical Research Council Cognitive Function and Ageing Study Collaborators. Survival time in people with dementia: analysis from population based cohort study with 14 year follow-up. BMJ 2008; 336: 258-262
30. Curtis L. Unit costs of health and social care. London: Personal Social Services Research Unit, 2007 [online]. Available from URL: http://www.pssru.ac. uk/pdf/uc/uc2007/ uc2007.pdf [Accessed 2008 Dec 9]
31. Macdonald A, Cooper B. Long-term care dementia services: an impending crisis. Age Ageing 2007; 36: 16-22
32. HMRevenue and Customs. Nationalminimumwage: archived rates [online]. Available fromURL: http://www.hmrc.gov.uk/ nmw/archived-rates.htm [Accessed 2010 Feb 6]
33. Jonsson L, Andreasen N, Kilander L, et al. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 2006; 20 (1): 49-55
34. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271-292
35. Tun S, Murman D, Long H, et al. Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. Am J Geriatr Psychiatry 2007; 15 (4): 314-327
36. Ward A, Caro JJ, Getsios D, et al. Asessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriat Psychiatry 2003; 18: 740-747 (Pubitemid 37009757)